Treatment resistance and metastasis depend on cellular plasticity. In this process the cancer cells switch from a non-motile and well-differentiated phenotype to a migratory and de-differentiated phenotype. We are investigating the intrinsic and extrinsic factors/mechanisms involved in such cellular plasticity aiming to identify molecular nodes that can be utilized as targets for anti-cancer treatment. The project group headed by Prof Kristin Austlid Taskén is studying neuronal differentiation of prostate cancer, while the Lina Prasmickaite project group is focusing on phenotype switching in breast cancer and melanomas.
Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
J Control Release, 349, 1 (in press)
Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
Front Oncol, 12, 873516
Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
RSC Adv, 9 (63), 37092-37100